Ardelyx announced XPHOZAH is now available for shipment to partner pharmacies. XPHOZAH is indicated to reduce serum phosphorus in adults with chronic kidney disease on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. XPHOZAH is a single tablet taken twice daily that offers a first-in-class mechanism of action that blocks phosphate absorption through its primary pathway. “The kidney community has been waiting a long time for another option to help manage hyperphosphatemia and we are proud to announce that XPHOZAH is now being shipped to our partner pharmacies,” said Mike Raab, president and chief executive officer of Ardelyx. “We look forward to engaging with healthcare providers and supporting patient access and affordability for this new therapeutic option with a differentiated mechanism of action.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ARDX:
- Ardelyx Shares Positive Data from Studies of XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor, at ASN Kidney Week 2023
- Ardelyx shares data from studies of XPHOZAH at ASN Kidney Week 2023
- Biotech Alert: Searches spiking for these stocks today
- Ardelyx price target raised to $11 from $9 at H.C. Wainwright
- Ardelyx Reports Third Quarter 2023 Financial Results and Updates 2023 U.S. IBSRELA® Net Sales Revenue Guidance